Key PointsQuestionDoes the presence of polyvascular disease affect the risk of ischemic events, both cardiac and limb, and bleeding in patients with peripheral artery disease? FindingsIn this secondary analysis of a randomized clinical trial of 13 885 patients with peripheral artery disease randomized to receive ticagrelor or clopidogrel compared with patients with isolated peripheral artery disease, those with concomitant peripheral artery disease and polyvascular disease had an increased risk of major adverse cardiac events and lower-extremity revascularization. Polyvascular disease was not associated with an increased risk of Thrombolysis in Myocardial Infarction major bleeding. MeaningThese data highlight the increased risk of coronary artery disease and cerebrovascular disease among patients with peripheral artery disease and the need to identify potent preventive antithrombotic therapies.
JAMA Network Open – American Medical Association
Published: Nov 30, 2018